Complete financial analysis of Arrowhead Pharmaceuticals, Inc. (ARWR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arrowhead Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Precision Wires India Limited (PRECWIRE.NS) Income Statement Analysis – Financial Results
- Priority Income Fund, Inc. (PRIF-PJ) Income Statement Analysis – Financial Results
- Adeka Corporation (4401.T) Income Statement Analysis – Financial Results
- ATIF Holdings Limited (ATIF) Income Statement Analysis – Financial Results
- IS DongSeo Co., Ltd. (010780.KS) Income Statement Analysis – Financial Results
Arrowhead Pharmaceuticals, Inc. (ARWR)
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.55M | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158.33K | 382.00K | 175.00K | 290.27K | 146.88K | 296.14K | 620.10K | 3.77M | 1.30M | 1.21M | 595.46K | 590.68K | 196.31K | 0.00 | 2.27K | 9.31K | 24.88K | 37.00K | 60.38K | 76.59K |
| Cost of Revenue | 0.00 | 0.00 | 10.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 724.09K | 0.00 | 0.00 | 0.00 | 0.00 | 87.00 | 6.30K | 2.09K | 2.85K | 33.79K | 36.97K |
| Gross Profit | 3.55M | 240.74M | 232.81M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158.33K | 382.00K | 175.00K | 290.27K | 146.88K | 296.14K | 620.10K | 3.77M | 1.30M | 483.93K | 595.46K | 590.68K | 196.31K | 0.00 | 2.18K | 3.02K | 22.78K | 34.15K | 26.59K | 39.62K |
| Gross Profit Ratio | 100.00% | 100.00% | 95.72% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.06% | 100.00% | 100.00% | 100.00% | 0.00% | 96.16% | 32.38% | 91.58% | 92.29% | 44.04% | 51.73% |
| Research & Development | 505.87M | 353.19M | 297.31M | 206.34M | 128.87M | 81.05M | 52.97M | 31.69M | 41.45M | 57.41M | 23.14M | 8.71M | 5.39M | 3.28M | 1.11M | 8.97M | 12.14M | 20.93M | 8.58M | 3.79M | 793.35K | 3.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 98.76M | 90.93M | 124.43M | 80.98M | 52.28M | 26.56M | 19.11M | 32.02M | 41.00M | 34.72M | 24.42M | 11.69M | 14.10M | 5.23M | 8.00M | 14.14M | 6.85B | 4.39B | 5.03B | 2.68M | 914.85K | 0.00 | 0.00 | 0.00 | 0.00 | 56.18K | 12.44K | 11.28K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.82B | -4.37B | -5.02B | 3.32M | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 34.18K | 38.14K | 78.48K |
| SG&A | 98.76M | 90.93M | 124.43M | 80.98M | 52.28M | 26.56M | 19.11M | 32.02M | 41.00M | 34.72M | 24.42M | 11.69M | 14.10M | 5.23M | 8.00M | 14.14M | 23.75M | 17.09M | 12.26M | 5.99M | 2.17M | 91.06K | 143.80K | 109.28K | 132.02K | 90.36K | 50.58K | 89.76K |
| Other Expenses | 0.00 | 1.62M | 5.80M | 2.07M | -582.52K | 0.00 | 7.49K | 1.31M | 57.35K | 417.87K | 82.09K | -997.98K | 9.41B | 3.03B | 5.13B | 9.87B | 17.31B | 7.65B | 8.22B | 3.32M | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M | 72.08M | 68.40M | 79.85M | 96.36M | 51.28M | 23.57M | 21.24M | 10.13M | 9.42M | 23.50M | 36.31M | 38.43M | 21.84M | 9.95M | 2.97M | 94.44K | 1.42M | 109.28K | 132.02K | 90.36K | 68.89K | 198.24K |
| Cost & Expenses | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M | 72.08M | 68.40M | 79.85M | 96.36M | 51.28M | 23.57M | 21.24M | 10.13M | 9.42M | 23.50M | 36.31M | 39.16M | 21.84M | 9.95M | 2.97M | 94.44K | 1.42M | 115.58K | 134.11K | 93.21K | 102.67K | 235.21K |
| Interest Income | 22.72M | 15.30M | 5.03M | 6.12M | 9.19M | 6.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.67K | 736.34M | 0.00 | 0.00 | 151.05K | 33.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 32.35M | 18.33M | 5.03M | 6.12M | 9.19B | 6.96B | 1.05B | 415.13M | 265.79M | 729.16M | 645.49M | 0.00 | 35.97M | 86.53M | 0.00 | 150.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 18.60M | 12.49M | 10.42M | 8.27M | 5.94M | 4.44M | 4.70M | 4.69M | 3.26M | 2.34M | 1.35M | 1.75M | 1.75M | 267.98K | 654.69K | 994.60K | 1.13M | 1.00M | 886.96K | 644.01K | 74.74K | 90.00 | 9.08K | 3.53K | 7.62K | 8.12K | 18.31K | 103.79K |
| EBITDA | -561.51M | -175.67M | -162.29M | -132.58M | -87.22M | 65.63M | -51.24M | -29.69M | -78.46M | -89.60M | -47.38M | -20.11M | -19.34M | -8.52M | -6.68M | -18.16M | -33.25M | -35.68M | -19.43M | -8.95M | -2.67M | -94.35K | -1.41M | -102.74K | -101.61K | -48.10K | -15.11K | -54.83K |
| EBITDA Ratio | -15,812.81% | -72.97% | -73.39% | -101.79% | -99.12% | 38.88% | -320.08% | -105.69% | -46,787.48% | -25,268.65% | -23,710.47% | -5,114.27% | -12,611.40% | -3,607.83% | -1,585.65% | -499.08% | -2,598.92% | -3,058.36% | -3,303.39% | -1,878.10% | -1,366.25% | 0.00% | -64,419.02% | -1,750.46% | -785.70% | 428.30% | -92.33% | 837.03% |
| Operating Income | -601.08M | -205.00M | -178.51M | -149.04M | -93.16M | 61.19M | -55.94M | -37.00M | -81.74M | -95.97M | -53.28M | -24.59M | -21.09M | -9.83M | -8.80M | -19.73M | -35.00M | -37.95M | -21.24M | -9.36M | -2.77M | -94.44K | -1.42M | -106.27K | -109.24K | -56.22K | -42.30K | -158.62K |
| Operating Income Ratio | -16,927.06% | -85.16% | -73.39% | -107.77% | -105.87% | 36.25% | -346.52% | -117.79% | -51,627.09% | -25,124.08% | -30,443.59% | -8,471.29% | -14,358.61% | -3,319.48% | -1,419.46% | -522.87% | -2,685.89% | -3,141.43% | -3,567.11% | -1,585.07% | -1,410.50% | 0.00% | -62,498.41% | -1,141.16% | -439.08% | -151.94% | -70.05% | -207.10% |
| Total Other Income/Expenses | -11.38M | -1.49M | 5.80M | 8.19M | 8.61M | 6.96M | 1.49M | 2.62M | 22.12K | 4.04M | -5.44M | -7.11M | -1.02M | 1.05M | 1.42M | -1.87M | -2.65M | -8.33M | 169.58K | 2.76M | 272.75K | 0.00 | 1.17M | -79.56K | -28.32K | -312.24K | -140.73K | -695.92K |
| Income Before Tax | -612.46M | -206.49M | -172.71M | -140.85M | -84.55M | 68.15M | -54.45M | -34.38M | -81.72M | -91.94M | -58.72M | -31.70M | -22.11M | -8.79M | -7.34M | -19.16M | -35.12M | -37.95M | -21.92M | -6.99M | -2.50M | -94.44K | -246.21K | -185.82K | -137.55K | -368.46K | -10.54K | -854.54K |
| Income Before Tax Ratio | -17,247.54% | -85.78% | -71.01% | -101.85% | -96.09% | 40.37% | -337.30% | -109.46% | -51,613.12% | -24,067.67% | -33,554.35% | -10,922.08% | -15,054.05% | -2,966.52% | -1,183.10% | -507.73% | -2,694.70% | -3,141.40% | -3,681.87% | -1,183.02% | -1,271.56% | 0.00% | -10,865.27% | -1,995.50% | -552.91% | -995.89% | -17.45% | -1,115.73% |
| Income Tax Expense | -2.77M | 2.78M | 3.79M | 2.00K | 2.40K | 173.55K | 2.40K | 2.40K | 2.40K | 2.40K | 5.30K | 6.22M | -203.44K | -6.86M | -3.25M | 53.95K | -8.03M | -8.02M | -2.24M | -2.74M | 800.00 | 800.00 | -1.17M | 79.56K | 28.32K | -649.22K | 9.32K | 695.92K |
| Net Income | -599.49M | -205.28M | -176.49M | -140.85M | -84.55M | 67.97M | -54.45M | -34.38M | -81.72M | -91.94M | -58.63M | -31.14M | -21.13M | -3.13M | -5.77M | -19.31M | -27.09M | -29.93M | -19.00M | -6.62M | -2.50M | -95.24K | -246.21K | -185.82K | -137.55K | 593.00K | -51.62K | -854.54K |
| Net Income Ratio | -16,882.37% | -85.27% | -72.56% | -101.85% | -96.09% | 40.27% | -337.32% | -109.46% | -51,614.64% | -24,068.29% | -33,502.97% | -10,729.22% | -14,383.61% | -1,056.56% | -931.15% | -511.73% | -2,078.65% | -2,477.70% | -3,190.35% | -1,121.55% | -1,271.96% | 0.00% | -10,865.27% | -1,995.50% | -552.91% | 1,602.80% | -85.49% | -1,115.73% |
| EPS | -5.00 | -1.91 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 | -1.30 | -1.90 | -0.44 | -0.90 | -4.27 | -6.91 | -8.35 | -5.95 | -2.61 | -1.88 | -0.25 | -32.47 | -25.97 | -19.48 | 97.40 | -10.16 | -175.33 |
| EPS Diluted | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 | -1.30 | -1.90 | -0.44 | -0.90 | -4.27 | -6.91 | -8.35 | -5.95 | -2.61 | -1.88 | -0.25 | -32.47 | -25.97 | -19.48 | 97.40 | -10.16 | -175.33 |
| Weighted Avg Shares Out | 119.78M | 107.31M | 105.43M | 103.75M | 100.72M | 93.86M | 83.64M | 73.15M | 60.99M | 57.36M | 46.90M | 23.96M | 11.12M | 7.18M | 6.43M | 4.52M | 3.92M | 3.59M | 3.20M | 2.54M | 1.33M | 373.88K | 7.58K | 7.15K | 7.06K | 6.09K | 5.08K | 4.87K |
| Weighted Avg Shares Out (Dil) | 119.78M | 106.75M | 105.43M | 103.75M | 100.72M | 98.61M | 83.64M | 73.90M | 61.05M | 57.36M | 46.93M | 24.00M | 11.13M | 7.18M | 6.43M | 4.52M | 3.92M | 3.59M | 3.20M | 2.54M | 1.33M | 373.88K | 7.58K | 7.15K | 7.06K | 6.09K | 5.08K | 4.87K |
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's second investigational RNA interference (RNAi) therapeutic being developed as a...
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30...
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP...
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results....
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical,...
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and...
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral...
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of Plozasiran (ARO-APOC3),...
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community affected by Familial Chylomicronemia Syndrome (FCS)....
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company's Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4)...
Source: https://incomestatements.info
Category: Stock Reports